Michaela Diamant Selected Research

Exenatide (Byetta)

1/2018	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
2/2017	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
1/2017	Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
10/2016	GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
10/2016	Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.
4/2016	Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
1/2016	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
10/2015	Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.
6/2015	GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.
6/2014	Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michaela Diamant Research Topics

Disease

86	Type 2 Diabetes Mellitus (MODY) 03/2019 - 11/2002
32	Insulin Resistance 01/2020 - 01/2003
18	Overweight 03/2019 - 01/2009
14	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/2021 - 04/2006
13	Weight Loss (Weight Reduction) 01/2021 - 12/2009
12	Obesity 10/2015 - 04/2005
11	Glucose Intolerance 03/2016 - 01/2010
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2015 - 11/2002
10	Body Weight (Weight, Body) 01/2020 - 05/2009
9	Cardiovascular Diseases (Cardiovascular Disease) 07/2011 - 10/2006
8	Hypertension (High Blood Pressure) 11/2013 - 01/2009
5	Non-alcoholic Fatty Liver Disease 10/2020 - 10/2006
5	Heart Failure 11/2015 - 04/2009
5	Hyperglycemia 10/2014 - 06/2012
4	Hypoglycemia (Reactive Hypoglycemia) 10/2017 - 04/2012
4	Myocardial Infarction 02/2014 - 05/2004
4	Diabetic Cardiomyopathies 10/2013 - 11/2008
3	Diabetes Mellitus 08/2015 - 05/2004
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2014 - 07/2011
3	Ischemia 07/2011 - 04/2009
2	Hyperemia 01/2017 - 01/2014
2	Fibrosis (Cirrhosis) 12/2016 - 01/2008
2	Abdominal Obesity 05/2015 - 03/2005
2	Diabetic Nephropathies (Diabetic Nephropathy) 02/2014 - 05/2010
2	Weight Gain 01/2014 - 12/2013
2	Inflammation (Inflammations) 03/2012 - 06/2007
2	Heart Diseases (Heart Disease) 04/2009 - 11/2008

Drug/Important Bio-Agent (IBA)

44	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 03/2007
28	Insulin (Novolin)FDA Link 01/2020 - 01/2003
23	Exenatide (Byetta)FDA Link 01/2018 - 10/2006
18	Metformin (Glucophage)FDA LinkGeneric 12/2017 - 01/2003
17	Triglycerides (Triacylglycerol)IBA 10/2020 - 01/2003
14	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 12/2009
14	Glucagon-Like Peptide-1 ReceptorIBA 03/2019 - 12/2009
12	Insulin Glargine (Lantus)FDA Link 01/2019 - 05/2009
11	Liraglutide FDA Link 03/2019 - 05/2012
9	LipidsIBA 03/2016 - 11/2007
8	Sitagliptin Phosphate (Januvia)FDA Link 03/2019 - 03/2014
8	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2017 - 09/2013
7	GlucocorticoidsIBA 03/2014 - 04/2010
6	Blood Glucose (Blood Sugar)IBA 10/2017 - 01/2003
6	Prednisolone (Predate)FDA LinkGeneric 03/2014 - 04/2010
6	HDL CholesterolIBA 07/2013 - 01/2003
6	Alanine Transaminase (SGPT)IBA 06/2010 - 11/2005
5	EnzymesIBA 03/2017 - 10/2006
5	Pharmaceutical PreparationsIBA 12/2016 - 05/2009
5	Pioglitazone (Actos)FDA Link 04/2014 - 01/2003
5	Arginine (L-Arginine)FDA Link 03/2014 - 01/2010
4	Dipeptidyl-Peptidase IV InhibitorsIBA 03/2019 - 06/2012
4	lixisenatideIBA 01/2019 - 09/2016
4	Glucagon-Like Peptides (Enteroglucagon)IBA 12/2016 - 02/2014
4	Fatty Acids (Saturated Fatty Acids)IBA 03/2016 - 12/2007
4	CholesterolIBA 01/2013 - 01/2003
4	LDL CholesterolIBA 01/2013 - 01/2003
4	Adenosine Triphosphate (ATP)IBA 07/2010 - 07/2003
4	CarbohydratesIBA 06/2010 - 07/2007
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 08/2010
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019 - 10/2009
3	insulin glulisine FDA Link 01/2019 - 12/2017
3	Adenosine (Adenocard)FDA LinkGeneric 01/2017 - 12/2006
3	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 12/2016 - 11/2015
3	Hypoglycemic Agents (Hypoglycemics)IBA 09/2016 - 03/2013
3	IncretinsIBA 11/2015 - 10/2006
3	CalciumIBA 01/2014 - 06/2012
3	Immunoglobulin M (IgM)IBA 05/2013 - 04/2011
3	Dobutamine FDA LinkGeneric 07/2011 - 04/2009
3	Phosphates (Orthophosphate)IBA 10/2009 - 07/2003
3	Adenine NucleotidesIBA 03/2007 - 04/2005
3	Acyl Coenzyme A (Acyl CoA)IBA 03/2007 - 04/2005
2	ApolipoproteinsIBA 08/2021 - 07/2010
2	HDL LipoproteinsIBA 10/2020 - 01/2003
2	CreatinineIBA 12/2017 - 11/2016
2	Glucagon-Like Peptide ReceptorsIBA 12/2017 - 02/2011
2	AlbuminsIBA 12/2017 - 11/2016
2	PlacebosIBA 12/2016 - 11/2016
2	GoldIBA 11/2016 - 08/2015
2	Vitamin D FDA LinkGeneric 02/2015 - 07/2012
2	imegliminIBA 07/2014 - 03/2013
2	C-PeptideIBA 03/2014 - 04/2013
2	Isophane Insulin (NPH Insulin)FDA Link 01/2014 - 12/2013
2	Insulin Detemir (Levemir)FDA Link 01/2014 - 12/2013
2	Proteins (Proteins, Gene)FDA Link 09/2013 - 08/2011
2	PalmitatesIBA 02/2013 - 11/2012
2	AdipokinesIBA 01/2013 - 07/2011
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2013 - 07/2002
2	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2012 - 09/2010
2	N 30IBA 06/2012 - 09/2010
2	prednylidene (Pred)IBA 11/2011 - 02/2011
2	Valsartan (Vals)FDA Link 10/2011 - 04/2011
2	Angiotensin Receptor AntagonistsIBA 10/2011 - 04/2011
2	glimepiride (Amarel)FDA LinkGeneric 07/2010 - 11/2008
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2010 - 09/2008
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 06/2010 - 12/2006
2	Nonesterified Fatty Acids (NEFA)IBA 10/2009 - 12/2007
2	ThiazolidinedionesIBA 11/2008 - 01/2003
2	Rosiglitazone (Avandia)FDA Link 11/2008 - 01/2003

Therapy/Procedure

26	Therapeutics 01/2019 - 07/2002
7	Glycemic Control 08/2015 - 04/2009
2	Gastric Bypass (Roux-en-Y Gastric Bypass) 11/2017 - 01/2015
2	Injections 11/2016 - 06/2014